{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:05:12Z","timestamp":1792692312265,"version":"4.5.0"},"reference-count":80,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Although cancer and diabetes are common diseases, the relationship between diabetes, neuropathy and the risk of developing peripheral sensory neuropathy while or after receiving chemotherapy is uncertain. In this review, we highlight the effects of chemotherapy on the onset or progression of neuropathy in diabetic patients. We searched the literature in Medline and Scopus, covering all entries until 31 January 2021. The inclusion and exclusion criteria were: (1) original article (2) full text published in English or Spanish; (3) neuropathy was specifically assessed (4) the authors separately analyzed the outcomes in diabetic patients. A total of 259 papers were retrieved. Finally, eight articles fulfilled the criteria, and four more articles were retrieved from the references of the selected articles. The analysis of the studies covered the information about neuropathy recorded in 768 cancer patients with diabetes and 5247 control cases (non-diabetic patients). The drugs investigated are chemotherapy drugs with high potential to induce neuropathy, such as platinum derivatives and taxanes, which are currently the mainstay of treatment of various cancers. The predisposing effect of co-morbid diabetes on chemotherapy-induced peripheral neuropathy depends on the type of symptoms and drug used, but manifest at any drug regimen dosage, although greater neuropathic signs are also observed at higher dosages in diabetic patients. The deleterious effects of chemotherapy on diabetic patients seem to last longer, since peripheral neuropathy persisted in a higher proportion of diabetic patients than non-diabetic patients for up to two years after treatment. Future studies investigating the risk of developing peripheral neuropathy in cancer patients with comorbid diabetes need to consider the duration of diabetes, cancer-induced neuropathic effects per se (prior chemotherapy administration), and the effects of previous cancer management strategies such as radiotherapy and surgery.<\/jats:p>","DOI":"10.3390\/curroncol28040273","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T04:13:54Z","timestamp":1629346434000},"page":"3124-3138","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4161-276X","authenticated-orcid":false,"given":"Mar","family":"Sempere-Bigorra","sequence":"first","affiliation":[{"name":"Department of Nursing, University of Valencia, 46010 Valencia, Spain"},{"name":"Frailty Research Organized Group (FROG), University of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Juli\u00e1n-Rochina","sequence":"additional","affiliation":[{"name":"Department of Nursing, University of Valencia, 46010 Valencia, Spain"},{"name":"Frailty Research Organized Group (FROG), University of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5669-4943","authenticated-orcid":false,"given":"Omar","family":"Cauli","sequence":"additional","affiliation":[{"name":"Department of Nursing, University of Valencia, 46010 Valencia, Spain"},{"name":"Frailty Research Organized Group (FROG), University of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jamaoncol.2016.3620","article-title":"Highlights of recent findings on quality-of-life management for patients with cancer and their survivors","volume":"2","author":"Shapiro","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00520-016-3404-y","article-title":"A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN)","volume":"25","author":"Schloss","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11764-015-0429-z","article-title":"The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients: Results from the PROFILES registry","volume":"9","author":"Vissers","year":"2015","journal-title":"J. Cancer Surviv."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/MJT.0b013e3181a3e50b","article-title":"Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer","volume":"17","author":"Nurgalieva","year":"2010","journal-title":"Am. J. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clcc.2012.05.002","article-title":"The effect of diabetes on oxaliplatin-induced peripheral neuropathy","volume":"11","author":"Uwah","year":"2012","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and cancer: A consensus report","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/157339912799424519","article-title":"Type 2 Diabetes and Obesity Metabolic Interactions: Common Factors for Breast Cancer Risk and Novel Approaches to Prevention and Therapy","volume":"8","year":"2012","journal-title":"Curr. Diabetes Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/14740338.2017.1361401","article-title":"Diabetes drugs and the incidence of solid cancers: A survey of the current evidence","volume":"16","author":"Tuccori","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.seminoncol.2017.10.004","article-title":"Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development","volume":"44","author":"Wilde","year":"2017","journal-title":"Semin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.2040-1124.2010.00070.x","article-title":"Mechanism of diabetic neuropathy: Where are we now and where to go?","volume":"2","author":"Soroku","year":"2011","journal-title":"J. Diabetes Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ejphar.2018.06.034","article-title":"Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets","volume":"833","author":"Dewanjee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","article-title":"Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials","volume":"34","author":"Hershman","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2011.39.8446","article-title":"Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer","volume":"30","author":"Schneider","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/15376516.2019.1600086","article-title":"Doxorubicin-induced neurotoxicity is associated with acute alterations in synaptic plasticity, apoptosis, and lipid peroxidation","volume":"29","author":"Alhowail","year":"2019","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/CMAR.S44261","article-title":"Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature","volume":"6","author":"Argyriou","year":"2014","journal-title":"Cancer Manag. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1200\/JCO.2004.08.048","article-title":"Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342","volume":"22","author":"Winer","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"iv45","DOI":"10.1093\/neuonc\/nos203","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention","volume":"14","author":"Grisold","year":"2012","journal-title":"Neuro. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00001813-200004000-00004","article-title":"Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: Results of a compassionate use program in The Netherlands","volume":"11","author":"Kruijtzer","year":"2000","journal-title":"Anticancer Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1111\/jns.12335","article-title":"Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment","volume":"24","author":"Staff","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00007853","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"249","author":"Quasthoff","year":"2002","journal-title":"J. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced peripheral neurotoxicity (CIPN): An update","volume":"82","author":"Argyriou","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.bulcan.2014.08.001","article-title":"Efficacit\u00e9 et tol\u00e9rance du trastuzumab en association avec oxaliplatine et fluoropyrimidine; pour des patients avec ad\u00e9nocarcinome m\u00e9tastatique de l\u2019estomac ou de la jonction \u0153so-gastrique: Une \u00e9tude r\u00e9trospective","volume":"102","author":"Soularue","year":"2015","journal-title":"Bull. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: A critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/843019","article-title":"Neurotoxicity Caused by the Treatment with Platinum Analogues","volume":"2011","author":"Amptoulach","year":"2011","journal-title":"Chemother. Res. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1007\/s00520-019-05112-5","article-title":"Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: Sub-group analysis of a randomized phase III study","volume":"28","author":"Wu","year":"2020","journal-title":"Support. Care Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1470-2045(07)70041-4","article-title":"Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial","volume":"8","author":"Ruiz","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.12691\/ajmcr-8-3-2","article-title":"Simultaneous Cardiotoxicity and Neurotoxicity Associated with 5-fluorouracil Containing Chemotherapy: A Case Report and Literature Review","volume":"8","author":"Ray","year":"2020","journal-title":"Am. J. Med. Case Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ajem.2017.07.022","article-title":"Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy","volume":"35","author":"Nguyen","year":"2017","journal-title":"Am. J. Emerg. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5301\/tj.5000652","article-title":"A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity","volume":"104","author":"Esin","year":"2018","journal-title":"Tumori"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0090-8258(90)90127-7","article-title":"5-Fluorouracil neurotoxicity","volume":"36","author":"Moore","year":"1990","journal-title":"Gynecol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.advms.2020.04.001","article-title":"Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies","volume":"65","author":"Pellacani","year":"2020","journal-title":"Adv. Med. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0140-6736(05)78426-9","article-title":"Gemcitabine-associated autonomic neuropathy","volume":"351","author":"Dormann","year":"1998","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2165\/00003495-200363150-00003","article-title":"Neurotoxic Complications of Chemotherapy in Patients with Cancer","volume":"63","author":"Verstappen","year":"2003","journal-title":"Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.expneurol.2016.06.016","article-title":"Epidermal innervation as a tool to study human axonal regeneration and disease progression","volume":"287","author":"Khoshnoodi","year":"2017","journal-title":"Exp. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"Figer","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.6004\/jnccn.2015.0057","article-title":"Delayed recovery and increased severity of paclitaxel-induced peripheral neuropathy in patients with diabetes","volume":"13","author":"Urrego","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/dmrr.856","article-title":"Neuropathy: Mobility and quality of life","volume":"24","year":"2008","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/dme.12196","article-title":"Amputations and foot ulcers in patients newly diagnosed with type 2 diabetes mellitus and observed for 19 years. The role of age, gender and co-morbidity","volume":"30","author":"Bruun","year":"2013","journal-title":"Diabet. Med."},{"key":"ref_39","first-page":"125","article-title":"Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens","volume":"32","author":"Bano","year":"2019","journal-title":"Pak. J. Pharm. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00520-015-2898-z","article-title":"Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: A single-center retrospective study","volume":"24","author":"Kus","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/annonc\/mdp509","article-title":"Incidence and evolution of oxaliplatin-induced eripheral sensory neuropathy in diabetic patients with colorectal cancer: A pooled analysis of three phase III studies","volume":"21","author":"Ramanathan","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12094-018-1939-8","article-title":"Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: A pooled analysis of two phase-III studies","volume":"21","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1006\/gyno.1996.0090","article-title":"The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer","volume":"61","author":"Gogas","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"ref_44","first-page":"1153","article-title":"Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer","volume":"33","author":"Kanbayashi","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s10147-011-0352-x","article-title":"Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer","volume":"18","author":"Tanabe","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1093\/brain\/awp219","article-title":"Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy","volume":"132","author":"Park","year":"2009","journal-title":"Brain"},{"key":"ref_47","first-page":"1187","article-title":"Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0","volume":"31","author":"Kaba","year":"2004","journal-title":"Gan To Kagaku Ryoho."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pain.2003.12.024","article-title":"Development and validation of the Neuropathic Pain Symptom Inventory","volume":"108","author":"Bouhassira","year":"2004","journal-title":"Pain"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0213-4853(10)70036-0","article-title":"Neuropat\u00eda inducida por quimioterapia: Un problema no resuelto","volume":"25","author":"Velasco","year":"2010","journal-title":"Neurologia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/j.pain.0000000000001540","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN): Where are we now?","volume":"160","author":"Colvin","year":"2019","journal-title":"Pain"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4185-0","article-title":"The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: A systematic review","volume":"18","author":"Gebremedhn","year":"2018","journal-title":"BMC Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-Induced Neuropathy and Its Association with Quality of Life Among 2- to 11-Year Colorectal Cancer Survivors: Results from the Population-Based PROFILES Registry","volume":"31","author":"Mols","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"102831","DOI":"10.1016\/j.critrevonc.2019.102831","article-title":"Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings","volume":"145","author":"Ibrahim","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1177\/1078155219898511","article-title":"Taxane-induced peripheral neuropathy and quality of life in breast cancer patients","volume":"26","author":"Salehifar","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/0284186X.2018.1556804","article-title":"Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy","volume":"58","author":"Soveri","year":"2019","journal-title":"Acta Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/IGC.0000000000001320","article-title":"The Influence of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life of Gynecologic Cancer Survivors","volume":"28","author":"Matsuoka","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2174\/1389201020666190102145305","article-title":"Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations","volume":"19","author":"Ceccarelli","year":"2019","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/dmrr.2486","article-title":"Steroid-induced diabetes: A clinical and molecular approach to understanding and treatment","volume":"30","author":"Hwang","year":"2014","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJMra1515442","article-title":"Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting","volume":"374","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_62","first-page":"CD007786","article-title":"Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood","volume":"2016","author":"Phillips","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","article-title":"Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy","volume":"94","author":"Vardy","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/1078155211409473","article-title":"Dexamethasone premedication for prophylaxis of taxane toxicities: Can the doses be reduced when paclitaxel or docetaxel are given weekly?","volume":"18","author":"Schwartz","year":"2012","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/1758834017698644","article-title":"Abiraterone acetate and prednisone in chemotherapy-na\u00efve prostate cancer patients: Rationale, evidence and clinical utility","volume":"9","author":"Crawford","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_66","unstructured":"Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., Bast, R.C., Gansler, T.S., Holland, J.F., and Frei, E. (2003). Corticosteroids in the Treatment of Neoplasms. Holland-Frei Cancer Medicine, BC Decker. [6th ed.]."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12020-017-1472-5","article-title":"Diagnostic work-up in steroid myopathy","volume":"60","author":"Minetto","year":"2018","journal-title":"Endocrine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11912-009-0072-9","article-title":"Neurotoxicity of Cancer Treatment","volume":"12","author":"Chamberlain","year":"2010","journal-title":"Curr. Oncol. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Zaj\u0105czkowska, R., Kocot-K\u0119pska, M., Leppert, W., Wrzosek, A., Mika, J., and Wordliczek, J. (2019). Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061451"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00019052-199810000-00015","article-title":"Metabolic neuropathies","volume":"11","author":"Comi","year":"1998","journal-title":"Curr. Opin. Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa032782","article-title":"Vascular Risk Factors and Diabetic Neuropathy","volume":"352","author":"Tesfaye","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1188\/08.CJON.243-247","article-title":"Evaluation and management of peripheral neuropathy in diabetic patients with cancer","volume":"12","author":"Visovsky","year":"2008","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/bja\/aet208","article-title":"Neuropathic pain in cancer","volume":"111","author":"Fallon","year":"2013","journal-title":"Br. J. Anaesth."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3904\/kjim.2018.162","article-title":"Neuropathic cancer pain: Prevalence, pathophysiology, and management","volume":"33","author":"Yoon","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1210\/jc.2017-01922","article-title":"Diabetic Microvascular Disease: An Endocrine Society Scientific Statement","volume":"102","author":"Barrett","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1474-4422(12)70065-0","article-title":"Diabetic neuropathy: Clinical manifestations and current treatments","volume":"11","author":"Callaghan","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_78","first-page":"1","article-title":"Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function","volume":"2016","year":"2016","journal-title":"J. Diabetes Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/674987","article-title":"Neuroinflammation and Oxidative Stress in Diabetic Neuropathy: Futuristic Strategies Based on These Targets","volume":"2014","author":"Sandireddy","year":"2014","journal-title":"Int. J. Endocrinol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejphar.2013.07.017","article-title":"Pathogenesis of diabetic neuropathy: Focus on neurovascular mechanisms","volume":"719","author":"Cotter","year":"2013","journal-title":"Eur. J. Pharmacol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/4\/273\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:47:00Z","timestamp":1760165220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/4\/273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["curroncol28040273"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28040273","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]}}}